Benoni E. Abboa‐Offei

Discovery and Preclinical Profile of Saxagliptin (BMS-477118):  A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

David J. Augeri, Jeffrey A. Robl, David A. Betebenner et al. · Journal of Medicinal Chemistry · 2005 · 621 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Dual Metalloprotease Inhibitors:  Mercaptoacetyl-Based Fused Heterocyclic Dipeptide Mimetics as Inhibitors of Angiotensin-Converting Enzyme and Neutral Endopeptidase

Jeffrey A. Robl, Chong‐Qing Sun, Jay Stevenson et al. · Journal of Medicinal Chemistry · 1997 · 198 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability:  Interplay between the N-Terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of α-Aminoacyl-<scp>l</scp>-<i>cis</i>-4,5-methanoprolinenitrile-Based Inhibitors

David R. Magnin, Jeffrey A. Robl, Richard Sulsky et al. · Journal of Medicinal Chemistry · 2004 · 103 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

Antihypertensive Activity During Inhibition of Neutral Endopeptidase and Angiotensin Converting Enzyme

Andrea A. Seymour, Joel N. Swerdel, Benoni E. Abboa‐Offei · Journal of Cardiovascular Pharmacology · 1991 · 86 citations

Medicine, Cardiology, Pharmacology +16

Evidence for a differential location of vasoconstrictor endothelin receptors in the vasculature

Suzanne Moreland, Diane M. McMullen, Benoni E. Abboa‐Offei et al. · British Journal of Pharmacology · 1994 · 63 citations · Full text

Life Sciences, Pharmacology, Physiology +14